Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment

A. Klukowska, V. Komrska, V. Vdovin, N. Zozulya, T. Lissitchkov, J. Oldenburg, CE. Ettingshausen,

. 2020 ; 11 (-) : 2040620720914692. [pub] 20200419

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20019314

Treatment of haemophilia A with FVIII replacement has evolved over the past decades to adapt to the needs of patients. octanate®, a plasma-derived, double virus-inactivated, von Willebrand factor (VWF)-containing FVIII concentrate, has been used in clinics worldwide for over 20 years. First licensed in 1998 in Germany, octanate® is approved in over 80 countries for the prevention and treatment of bleeding and for surgical prophylaxis in patients with haemophilia A, and in over 40 countries for immune tolerance induction (ITI). The manufacturing process for octanate® was developed to ensure high viral safety and effectively eliminates both enveloped and nonenveloped viruses. Over the past 20 years, the excellent safety and efficacy of octanate® have been demonstrated in pivotal clinical trials in adult and paediatric previously treated patients (PTPs) for on-demand treatment, prophylaxis and as surgical cover. Importantly, octanate® has displayed low immunogenicity in previously untreated patients (PUPs), with only 9.8% of PUPs developing FVIII inhibitors. octanate® has also shown to be highly effective in inhibitor elimination when used as ITI therapy. In a population of patients with high risk of ITI failure, success was achieved in 79.2% of patients (70.8% complete success), even when using exceptionally stringent success criteria. No relapses were observed. Here we present an overview of the clinical data with octanate® that support its use in a range of patient populations and clinical indications.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019314
003      
CZ-PrNML
005      
20201123123623.0
007      
ta
008      
201103s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2040620720914692 $2 doi
035    __
$a (PubMed)32341775
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Klukowska, Anna $u Department of Paediatric Oncology, Medical University of Warsaw, Haematology, Clinical Transplantology and Paediatrics, Warsaw, Poland.
245    10
$a octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment / $c A. Klukowska, V. Komrska, V. Vdovin, N. Zozulya, T. Lissitchkov, J. Oldenburg, CE. Ettingshausen,
520    9_
$a Treatment of haemophilia A with FVIII replacement has evolved over the past decades to adapt to the needs of patients. octanate®, a plasma-derived, double virus-inactivated, von Willebrand factor (VWF)-containing FVIII concentrate, has been used in clinics worldwide for over 20 years. First licensed in 1998 in Germany, octanate® is approved in over 80 countries for the prevention and treatment of bleeding and for surgical prophylaxis in patients with haemophilia A, and in over 40 countries for immune tolerance induction (ITI). The manufacturing process for octanate® was developed to ensure high viral safety and effectively eliminates both enveloped and nonenveloped viruses. Over the past 20 years, the excellent safety and efficacy of octanate® have been demonstrated in pivotal clinical trials in adult and paediatric previously treated patients (PTPs) for on-demand treatment, prophylaxis and as surgical cover. Importantly, octanate® has displayed low immunogenicity in previously untreated patients (PUPs), with only 9.8% of PUPs developing FVIII inhibitors. octanate® has also shown to be highly effective in inhibitor elimination when used as ITI therapy. In a population of patients with high risk of ITI failure, success was achieved in 79.2% of patients (70.8% complete success), even when using exceptionally stringent success criteria. No relapses were observed. Here we present an overview of the clinical data with octanate® that support its use in a range of patient populations and clinical indications.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Komrska, Vladimír $u Department of Paediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Vdovin, Vladimír $u Morozovskaya Children's Hospital, Moscow, Russian Federation.
700    1_
$a Zozulya, Nadezhda $u National Research Centre for Hematology, Moscow, Russian Federation.
700    1_
$a Lissitchkov, Toshko $u Department of Disorders of Haemostasis, SBALHZ - EAD, Sofia, Bulgaria.
700    1_
$a Oldenburg, Johannes $u Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
700    1_
$a Ettingshausen, Carmen Escuriola $u Haemophilia Centre Rhine Main GmbH, Hessenring 13a, Geb. G, Mörfelden-Walldorf, 64546, Germany.
773    0_
$w MED00205356 $t Therapeutic advances in hematology $x 2040-6207 $g Roč. 11, č. - (2020), s. 2040620720914692
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32341775 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123123622 $b ABA008
999    __
$a ind $b bmc $g 1586092 $s 1109512
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c - $d 2040620720914692 $e 20200419 $i 2040-6207 $m Therapeutic advances in hematology $n Ther Adv Hematol $x MED00205356
LZP    __
$a Pubmed-20201103

Najít záznam

Citační ukazatele

Možnosti archivace